Alumis Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, ALMS reported earnings of -1.06 USD per share (EPS) for Q3 25, missing the estimate of -0.93 USD, resulting in a -13.42% surprise. Revenue reached 2.07 million, compared to an expected 2.89 million, with a -28.51% difference. The market reacted with a +4.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.96 USD, with revenue projected to reach 2.89 million USD, implying an decrease of -9.43% EPS, and increase of 39.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Alumis Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alumis Inc. Common Stock reported EPS of -$1.06, missing estimates by -13.42%, and revenue of $2.07M, -28.51% below expectations.
How did the market react to Alumis Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 4.55%, changed from $5.28 before the earnings release to $5.52 the day after.
When is Alumis Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 17, 2026.
What are the forecasts for Alumis Inc. Common Stock's next earnings report?
Based on 10
analysts, Alumis Inc. Common Stock is expected to report EPS of -$0.96 and revenue of $2.89M for Q4 2025.